CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
LOS ANGELES--(BUSINESS WIRE)--Apr 4, 2007 - CytRx Corporation (NASDAQ:CYTR) today announced positive results of additional animal stroke studies indicating that CytRx's lead drug candidate arimoclomol significantly accelerated the recovery of sensory and motor function in an experimental rat model ...CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising mul...CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with ar...